{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:01:28Z","timestamp":1720382488067},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.leukres.2017.10.014","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T19:32:27Z","timestamp":1509132747000},"page":"28-33","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines"],"prefix":"10.1016","volume":"63","author":[{"given":"Wei-Hong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin-Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Chun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.10.014_bib0005","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.10.014_bib0010","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2146\/ajhp060526","article-title":"Novel treatment strategies for chronic myeloid leukemia","volume":"63","author":"Fausel","year":"2006","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.leukres.2017.10.014_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcmd.2016.03.005","article-title":"Simplifying procedure for prediction of resistance risk in CML patients \u2013 test of sensitivity to TKI ex vivo","volume":"58","author":"\u017d\u00e1\u010dkov\u00e1","year":"2016","journal-title":"Blood Cells. Mol. Dis."},{"key":"10.1016\/j.leukres.2017.10.014_bib0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJMcibr072412","article-title":"A new mechanism of leukemia drug resistance?","volume":"357","author":"Williams","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.10.014_bib0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nrm1128","article-title":"Rocks: multifunctional kinases in cell behaviour","volume":"4","author":"Riento","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.leukres.2017.10.014_bib0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7150\/ijms.5.263","article-title":"Eph receptors and ephrin signaling pathways: a role in bone homeostasis","volume":"5","author":"Edwards","year":"2008","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.leukres.2017.10.014_bib0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1186\/1471-2407-10-641","article-title":"Combination of Dll4\/Notch and Ephrin-B2\/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis","volume":"10","author":"Djokovic","year":"2010","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.014_bib0040","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1373\/clinchem.2003.026849","article-title":"Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers","volume":"50","author":"Hafner","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.leukres.2017.10.014_bib0045","first-page":"2913","article-title":"Effect of EPH-ephrin signaling on the growth of human leukemia cells","volume":"34","author":"Takahashi","year":"2014","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2017.10.014_bib0050","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s12032-013-0836-9","article-title":"Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4\/RhoA pathway in chronic myeloid leukemia cell lines","volume":"31","author":"Huang","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.leukres.2017.10.014_bib0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bcmd.2016.04.007","article-title":"EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells","volume":"59","author":"Zhang","year":"2016","journal-title":"Blood Cells. Mol. Dis."},{"issue":"1","key":"10.1016\/j.leukres.2017.10.014_bib0060","first-page":"7","article-title":"Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia","volume":"37","author":"Jiang","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.leukres.2017.10.014_bib0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-642-01222-8_7","article-title":"Dasatinib","volume":"184","author":"Lindauer","year":"2010","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.leukres.2017.10.014_bib0070","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: followup of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2017.10.014_bib0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00063030-200822010-00007","article-title":"Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"22","author":"Keam","year":"2008","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.leukres.2017.10.014_bib0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11899-016-0304-7","article-title":"Accelerated phase CML: outcomes in newly diagnosed vs. progression from chronic phase","volume":"11","author":"Mukherjee","year":"2016","journal-title":"Curr. Hematol. Malig Rep."},{"key":"10.1016\/j.leukres.2017.10.014_bib0085","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1038\/cddis.2013.519","article-title":"RhoA\/ROCK\/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo","volume":"5","author":"Li","year":"2014","journal-title":"Cell. Death. Dis."},{"key":"10.1016\/j.leukres.2017.10.014_bib0090","doi-asserted-by":"crossref","first-page":"135285","DOI":"10.1155\/2010\/135285","article-title":"Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis","volume":"2010","author":"Mosch","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.leukres.2017.10.014_bib0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrd4175","article-title":"Therapeutic targeting of EPH receptors and their ligands","volume":"13","author":"Boyd","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.leukres.2017.10.014_bib0100","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0092-8674(01)00391-9","article-title":"Signaling downstream of Eph receptors and ephrin ligands","volume":"105","author":"Schmucker","year":"2001","journal-title":"Cell"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T12:26:46Z","timestamp":1535286406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617305672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":20,"alternative-id":["S0145212617305672"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.10.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}